Gin Hwa Biotech, Inc.

As of June 30, 2026, Gin Hwa Biotech, Inc. carries a market capitalization of 1.73B, placing it among publicly traded companies globally. Its enterprise value stands at 1.88B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Gin Hwa Biotech, Inc. has 29.25M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Gin Hwa Biotech, Inc. maintains a current ratio of 1.78, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Gin Hwa Biotech, Inc. recorded 13.30M in income tax expense.

As of the close on October 22, 2026, Gin Hwa Biotech, Inc.'s stock has declined approximately 6.55% over the past 52 weeks. The 50-day moving average sits at 60.71, while the 200-day moving average is 66.00.

As of June 30, 2026, Gin Hwa Biotech, Inc. holds 74.71M in cash and equivalents against 224.34M in total debt, resulting in a net debt position of 140.60M. Total book value stands at 774.60M, with working capital of 168.23M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Gin Hwa Biotech, Inc.'s most recent stock split took place on July 27, 2026 with a 20:21 split ratio.